Hopeful Merck execs talk up early Belsomra launch results

Last month, Merck & Co. ($MRK) finally rolled out its long-awaited sleep drug, Belsomra (suvorexant). After years of delays and disappointments at the FDA, it's safe to say that no one expects the drug to churn out big sales this year. But that's not to say Merck doesn't have its ambitions. Report